LPCN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

116.00K

-96.68%

-0.610

-284.85%

100.00K

+6.54%

-0.600

+71.43%

-0.610

+48.78%

Estimates Revision

The market is revising No Change the revenue expectations for Lipocine Inc. (LPCN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 137.66%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.25%

In Past 3 Month

Stock Price

Go Up

+137.66%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast LPCN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

6.75

Averages

6.88

High

7.00

Current: 0.000

Low

6.75

Averages

6.88

High

7.00

H.C. Wainwright

Buy -> Buy

downgrade

$8 -> $7

2025-11-13

Reason

H.C. Wainwright

Price Target

$8 -> $7

2025-11-13

downgrade

Buy -> Buy

Reason

H.C. Wainwright lowered the firm's price target on Lipocine to $7 from $8 and keeps a Buy rating on the shares following the Q3 report.

H.C. Wainwright

Yi Chen

initiated

2025-05-29

Reason

H.C. Wainwright

Yi Chen

Price Target

2025-05-29

initiated

Reason

H.C. Wainwright analyst Yi Chen assumed coverage of Lipocine with a Buy rating and $8 price target. Lipocine's first commercialized product, Tlando, an oral treatment indicated for testosterone replacement therapy, was approved by the FDA in 2022 and its current lead pipeline candidate is LPCN 1154, which is a rapid onset, oral formulation of the neuroactive steroid brexanolone for the treatment of postpartum depression, the analyst tells investors. If successfully developed, LPCN 1154 could "bring significant value to the company," says the analyst, who notes that the firm's current valuation is primarily based on market prospects for LPCN 1154.

Valuation Metrics

The current forward P/E ratio for Lipocine Inc (LPCN.O) is -3.36, compared to its 5-year average forward P/E of -4.74. For a more detailed relative valuation and DCF analysis to assess Lipocine Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.74

Current PE

-3.36

Overvalued PE

-1.62

Undervalued PE

-7.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.08

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.35

Undervalued EV/EBITDA

-0.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

18.11

Current PS

106.77

Overvalued PS

37.29

Undervalued PS

-1.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LPCN News & Events

Events Timeline

No data

News

9.0

2025-12-16Newsfilter

Lipocine Achieves 80% Enrollment in Phase 3 PPD Trial, On Track for 2026 Results

9.0

2025-11-18PRnewswire

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

9.5

2025-11-06PRnewswire

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

People Also Watch

Frequently Asked Questions

What is Lipocine Inc (LPCN) stock price today?

The current price of LPCN is 7.51 USD — it has decreased -0.13 % in the last trading day.

What is Lipocine Inc (LPCN)'s business?

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.

What is the price predicton of LPCN Stock?

What is Lipocine Inc (LPCN)'s revenue for the last quarter?

Lipocine Inc revenue for the last quarter amounts to 114.57K USD, decreased % YoY.

What is Lipocine Inc (LPCN)'s earnings per share (EPS) for the last quarter?

Lipocine Inc. EPS for the last quarter amounts to -0.59 USD, increased 43.90 % YoY.

What changes have occurred in the market's expectations for Lipocine Inc (LPCN)'s fundamentals?

How many employees does Lipocine Inc (LPCN). have?

Lipocine Inc (LPCN) has 16 emplpoyees as of January 08 2026.

What is Lipocine Inc (LPCN) market cap?

Today LPCN has the market capitalization of 41.75M USD.